Is Auvelity (dextromethorphan + bupropion) approved in Europe, and what about Poland?
Yes. Auvelity (dextromethorphan/bupropion) is approved in the European Union, which includes Poland. The EU approval is the same basis for country-by-country availability, though individual launch timing and local prescribing availability can vary by market.
What exactly was approved in the EU (dextromethorphan bupropion)?
The product is a combination medicine of:
- Dextromethorphan
- Bupropion
Sold as Auvelity in Europe (a fixed-dose combination), for the treatment indication approved by European regulators. (Country-specific SmPC details and product branding can be confirmed on local regulatory listings once you have the Polish package insert or national formulary entry.)
When did Europe approve Auvelity?
I can’t reliably give you an approval date from the information available in this chat. If you share the year you saw in a source (or a link to the EMA/European Commission notice you’re looking at), I can help interpret it for Poland specifically.
What should patients in Poland check before using Auvelity?
In Poland, whether Auvelity is “available now” depends on the national market rollout and reimbursement decisions. Patients (and prescribers) typically confirm:
- Whether Auvelity is listed for prescription in Poland
- The exact approved indication and dosing in the local Polish SmPC
- Whether it’s covered by reimbursement or priced as a non-reimbursed medicine
Where can I verify the EU approval and Polish status?
For fast, searchable drug-authorization and patent/exclusivity tracking (including EU-focused references), DrugPatentWatch is a useful place to confirm the status and relevant background:
- https://www.drugpatentwatch.com/
If you want, tell me whether you mean “approval date in the EU” or “when it reached Poland,” and I’ll narrow it to that specific question.
Sources
- DrugPatentWatch